BRPI0916121A2 - "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição" - Google Patents

"métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição"

Info

Publication number
BRPI0916121A2
BRPI0916121A2 BRPI0916121A BRPI0916121A BRPI0916121A2 BR PI0916121 A2 BRPI0916121 A2 BR PI0916121A2 BR PI0916121 A BRPI0916121 A BR PI0916121A BR PI0916121 A BRPI0916121 A BR PI0916121A BR PI0916121 A2 BRPI0916121 A2 BR PI0916121A2
Authority
BR
Brazil
Prior art keywords
identifying
kit
composition
methods
prostate cancer
Prior art date
Application number
BRPI0916121A
Other languages
English (en)
Inventor
Arul M Chinnaiyan
Bo Han
Chandan Kumar
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of BRPI0916121A2 publication Critical patent/BRPI0916121A2/pt
Publication of BRPI0916121A8 publication Critical patent/BRPI0916121A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0916121A 2008-11-18 2009-11-18 métodos para identificar câncer de próstata, composição, kit, método para identificar a presença de uma fusão gênica e uso de uma composição BRPI0916121A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/272,865 US9957569B2 (en) 2005-09-12 2008-11-18 Recurrent gene fusions in prostate cancer
PCT/US2009/064957 WO2010059702A2 (en) 2008-11-18 2009-11-18 Recurrent gene fusions in prostate cancer

Publications (2)

Publication Number Publication Date
BRPI0916121A2 true BRPI0916121A2 (pt) 2015-11-03
BRPI0916121A8 BRPI0916121A8 (pt) 2018-06-19

Family

ID=41668351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916121A BRPI0916121A8 (pt) 2008-11-18 2009-11-18 métodos para identificar câncer de próstata, composição, kit, método para identificar a presença de uma fusão gênica e uso de uma composição

Country Status (10)

Country Link
US (1) US9957569B2 (pt)
EP (1) EP2358899A2 (pt)
JP (3) JP2012509068A (pt)
KR (1) KR20110084995A (pt)
CN (1) CN102812130A (pt)
AU (1) AU2009316693B2 (pt)
BR (1) BRPI0916121A8 (pt)
CA (1) CA2744059A1 (pt)
IL (1) IL212964A0 (pt)
WO (1) WO2010059702A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2814598A1 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008039774A1 (en) * 2006-09-25 2008-04-03 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2692793C (en) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
KR20110111474A (ko) * 2009-01-09 2011-10-11 더 리젠츠 오브 더 유니버시티 오브 미시간 암에서의 반복적 유전자 융합체
EP2435584B1 (en) 2009-05-26 2016-07-13 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulations
EP2478120B1 (en) 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
US9315802B2 (en) 2009-12-30 2016-04-19 Quest Diagnostics Investments Incorporated RNA isolation from soluble urine fractions
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2640854B1 (en) 2010-11-19 2018-02-21 The Regents Of The University Of Michigan PCAT1 ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2012092490A1 (en) 2010-12-30 2012-07-05 Quest Diagnostics Investments Incorporated Diagnosis of prostate cancer
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US9738887B2 (en) 2012-02-13 2017-08-22 Neumodx Molecular, Inc. Microfluidic cartridge for processing and detecting nucleic acids
US11648561B2 (en) 2012-02-13 2023-05-16 Neumodx Molecular, Inc. System and method for processing and detecting nucleic acids
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
WO2014066376A1 (en) * 2012-10-25 2014-05-01 Neumodx Molecular, Inc. Method and materials for isolation of nucleic acid materials
CN103336914B (zh) * 2013-05-31 2016-05-25 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
JP6907188B2 (ja) * 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CN106866824B (zh) * 2017-03-06 2020-10-27 哈尔滨医科大学 一种抗ddx5的全人源单克隆抗体及其制备方法和应用
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018175273A1 (en) 2017-03-21 2018-09-27 The Regents Of The University Of Michigan Erg targeted therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US10964410B2 (en) * 2017-05-25 2021-03-30 Koninklijke Philips N.V. System and method for detecting gene fusion
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
US10769307B2 (en) 2018-05-30 2020-09-08 Bank Of America Corporation Processing system using natural language processing for performing dataset filtering and sanitization
CN113528660A (zh) * 2020-09-18 2021-10-22 深圳汇芯生物医疗科技有限公司 前列腺癌的风险评估装置
CN112522404B (zh) * 2020-12-10 2023-06-09 珠海中科先进技术研究院有限公司 一种用于检测前列腺癌的多重荧光pcr试剂盒

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) * 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
GB2043675B (en) * 1979-03-08 1983-02-23 British Gas Corp Gas oil purification
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
ATE88761T1 (de) * 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5283174A (en) * 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4968103A (en) * 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
WO1991001384A1 (en) * 1989-07-11 1991-02-07 Gen-Probe, Incorporated Nucleic acid sequence amplification methods utilizing a transcription complex
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5455166A (en) * 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5270184A (en) * 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) * 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
EP0552108B1 (en) * 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP3448090B2 (ja) * 1994-02-16 2003-09-16 浜松ホトニクス株式会社 エネルギー移動検出法およびその装置
US20050214309A1 (en) * 1994-03-18 2005-09-29 Hinrichs Steven H Methods and compositions for modulating transcription factor activity
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
JP3189000B2 (ja) * 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5856125A (en) 1995-06-05 1999-01-05 The United States Of America As Represented By The Department Of Health And Human Services ETS2 repressor factor (ERF) genetic locus and its products
US5710029A (en) * 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
NZ331866A (en) * 1996-03-15 2000-05-26 Corixa Corp Compounds for immunotherapy and immunodiagnosis of prostate cancer
AU713667B2 (en) * 1996-04-12 1999-12-09 Phri Properties, Inc. Detection probes, kits and assays
WO1998015837A1 (en) 1996-10-07 1998-04-16 Meat And Livestock Commission Assay for duroc muscle fibre type
US7125969B1 (en) 1996-11-27 2006-10-24 The Regents Of The University Of California ETS-related gene overexpressed in human breast and epithelial cancers
PL196260B1 (pl) * 1997-02-25 2007-12-31 Corixa Corp Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030103981A1 (en) 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US6043033A (en) 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US20020119531A1 (en) 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
DE69837839T2 (de) * 1997-03-07 2007-12-13 Clare Chemical Research LLC, Denver Fluorometrischer Nachweis mit sichtbarem Light
US6080912A (en) * 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
DE69840669D1 (de) 1997-04-10 2009-04-30 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
IL139988A0 (en) 1998-06-01 2002-02-10 Urogenesys Inc Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO1999065929A1 (en) 1998-06-16 1999-12-23 The Regents Of The University Of California Exons 4 and 7 encode separate transactivating and chromatin localizing domains in esx
WO2000000605A1 (en) 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
AU762728B2 (en) * 1998-07-02 2003-07-03 Gen-Probe Incorporated Molecular torches
HUP0203035A3 (en) 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
WO2000012758A1 (en) 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
US6872811B1 (en) 1998-09-30 2005-03-29 Millennium Pharmaceuticals, Inc. HRPCa9 and HRPCa10 nucleic acids and polypeptides
CA2344550A1 (en) 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1131095A4 (en) 1998-10-19 2003-04-23 Diadexus Inc METHOD FOR DIAGNOSING, MONITORING, CLASSIFYING STAGES, VISUALIZING AND TREATING PROSTATE CANCER
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6828429B1 (en) * 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) * 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
WO2000065067A2 (en) 1999-04-23 2000-11-02 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
WO2000070092A1 (en) 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer
DE60014762T2 (de) * 1999-05-24 2005-10-13 Tosoh Corp., Shinnanyo Methode zum Nachweis von Ribonukleinsäuren
US20020168638A1 (en) 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
DE10004102A1 (de) 2000-01-31 2002-06-20 Metagen Pharmaceuticals Gmbh Nachweis von differenzieller Genexpression
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
WO2001088124A2 (en) 2000-05-16 2001-11-22 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of erg
NZ523715A (en) 2000-07-27 2004-07-30 Univ Australian A set of oligonucleotide probes 'promiscuous' probes that hybridise to target sequences common to more than one of the target polynucleotides
US7199137B2 (en) * 2000-09-21 2007-04-03 Smithkline Beecham Plc Imidazole derivatives as Raf kinase inhibitors
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20040009481A1 (en) 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US6537811B1 (en) 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
CA2466896A1 (en) 2001-09-06 2003-03-20 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
EP1592809B1 (en) 2003-02-07 2013-04-10 Diagnocure Inc. Method to detect prostate cancer in a sample
AU2004213432A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
US20070275915A1 (en) 2003-04-15 2007-11-29 Cell Genesys, Inc. Tmprss2 Regulatory Sequences and Uses Thereof
JP2006525027A (ja) * 2003-05-01 2006-11-09 ジェン−プロウブ インコーポレイテッド 分子スイッチを含むオリゴヌクレオチド
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2004113571A2 (en) 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
JP4574619B2 (ja) * 2003-09-05 2010-11-04 トーマス・ジェファーソン・ユニバーシティ 肝細胞癌の検査及び監視
US10066268B2 (en) 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
CN101018874A (zh) 2004-08-13 2007-08-15 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
CA2957197C (en) * 2004-08-27 2017-12-12 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US7638278B2 (en) * 2005-05-13 2009-12-29 The Board Of Trustees Of The Leland Stanford Junior University Markers of DNA copy number alteration for improved prognostication in prostate cancer
CA2814598A1 (en) * 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA3018520C (en) * 2006-10-10 2022-05-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
EP2604701B1 (en) 2007-07-06 2015-11-04 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20100305188A1 (en) * 2007-10-03 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of regulating the proliferation of cell
CN102439174B (zh) 2009-02-19 2015-02-04 康奈尔大学 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法
EP2478120B1 (en) 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer

Also Published As

Publication number Publication date
JP2018019720A (ja) 2018-02-08
WO2010059702A3 (en) 2010-07-29
AU2009316693A1 (en) 2010-05-27
CN102812130A (zh) 2012-12-05
BRPI0916121A8 (pt) 2018-06-19
IL212964A0 (en) 2011-07-31
US20090239221A1 (en) 2009-09-24
KR20110084995A (ko) 2011-07-26
JP2012509068A (ja) 2012-04-19
CA2744059A1 (en) 2010-05-27
JP2015177809A (ja) 2015-10-08
US9957569B2 (en) 2018-05-01
EP2358899A2 (en) 2011-08-24
WO2010059702A2 (en) 2010-05-27
AU2009316693B2 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
BRPI0916121A2 (pt) "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição"
BRPI0819338A2 (pt) Preparações, métodos e kits úteis para o tratamento de tosse
ZA201001789B (en) Composition and methods for use for antibodies against sclerostin
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0716872A2 (pt) Fosfolipases, ácidos nucléicos codificando-as e métodos para fabricação e uso delas
GB0820190D0 (en) Tissue excision tool, kits and methods of using the same
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
ZA200905886B (en) Methods and kits for administering probiotics
PL2371385T3 (pl) Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
IL197668A0 (en) Rna antagonist compounds for the modulation of pcsk9
BRPI0815138A2 (pt) Métodos e organismos para a produção acoplada a crescimento de 1,4-butanodiol
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
BRPI0814330A2 (pt) métodos e kits cirúrgicos
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
BRPI0909885A2 (pt) composição decorativa e método para sua utilização
EP2223121A4 (en) METHOD AND KIT FOR USE IN THE DIFFERENTIATION OF IBD AND IBS AND IN COMPLEMENTARY DISTINCTION BETWEEN DIFFERENT TYPES OF IBD DISEASES
BRPI0905990A2 (pt) "método cosmético, combinação, composição e kits"
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BRPI0811092A2 (pt) Método de determinação do grau de um tumor, e, uso de 1 3c-piruvato hiperpolarizado
NL1034834A1 (nl) Flavonoïde-rijke weefsels van Neomarica gracilis en werkwijzen om deze te kweken.
BRPI0718035A2 (pt) Método e disposição para fabricação de metanol
GB0603295D0 (en) Methods and kits

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements